Von Kobyletzki Laura, Metsini Alexandra, Regnell Simon E, Carlberg Michael, Svensson Åke, Antelmi Annarita
Clinical Epidemiology and Biostatistics, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Department of Occupational and Environmental Dermatology, Skåne University Hospital, Lund University, Malmö, Sweden.
Örebro University, School of Medical Sciences, Örebro, Sweden; Department of Healthcare, Knowledge Support Unit, Region Värmland, Sweden.
Acta Derm Venereol. 2025 Aug 18;105:adv43730. doi: 10.2340/actadv.v105.43730.
Prurigo nodularis (PN) is a chronic, itchy, inflammatory skin condition that negatively affects quality of life. A study was undertaken to investigate the healthcare utilization, including treatment patterns and direct costs for specialist care, for PN in Sweden. Linkage cohorts were created from national Swedish patient and prescription registers, and the cost-per-patient database of PN adults in specialist care in Sweden from 2015 to 2020. Around 875 patients were registered annually with a specialist diagnosis of PN in Sweden, with 3,548 specialist visits per year on average. In patients with severe PN with AD, the most common treatment sequence was topical treatment with corticosteroids followed by systemic prednisolone and methotrexate (32.6%). More than one-fifth of individuals with PN, and most with severe PN, had treatment for more than 1 year. For in- and outpatient care, the mean cost per visit was €458.6 and per patient per year around €1,862. The total annual cost of PN patients is estimated to be €1.6 million in Sweden. A high proportion of patients are treated for years with several, often systemic, treatment sequels. Targeted treatments for PN might improve patients' quality of life and reduce the high related costs for the healthcare system.
结节性痒疹（PN）是一种慢性、瘙痒性炎症性皮肤病，会对生活质量产生负面影响。瑞典开展了一项研究，以调查PN的医疗保健利用情况，包括治疗模式和专科护理的直接成本。通过瑞典国家患者和处方登记册以及2015年至2020年瑞典专科护理中PN成人的患者人均成本数据库创建了关联队列。瑞典每年约有875名患者被专科诊断为PN，平均每年有3548次专科就诊。在患有重度PN合并特应性皮炎（AD）的患者中，最常见的治疗顺序是外用皮质类固醇，随后是全身性泼尼松龙和甲氨蝶呤（32.6%）。超过五分之一的PN患者，以及大多数重度PN患者，接受治疗超过1年。对于门诊和住院护理，每次就诊的平均费用为458.6欧元，每位患者每年约为1862欧元。瑞典PN患者的年度总成本估计为160万欧元。很大一部分患者多年来接受多种治疗，通常是全身性治疗。针对PN的靶向治疗可能会改善患者的生活质量，并降低医疗系统的高额相关成本。
